Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesDermatologyAvMed Botox J0585 Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Botulinum toxin Type A (onabotulinumtoxinA) for primary axillary hyperhidrosis — Prior authorization / step-edit criteria

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This prior authorization/step-edit form governs medical approval requirements for Botox (onabotulinumtoxinA, J0585) used to treat primary axillary hyperhidrosis for AvMed members; it specifies documentation, clinical criteria, dosing limits, and prior therapy requirements that prescribers must meet.

    Policy Summary
    PayerAvMed
    PolicyBotulinum toxin Type A (onabotulinumtoxinA) for primary axillary hyperhidrosis — Prior authorization / step-edit criteria
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Last ReviewOct 15, 2024
    Next Review Date
    Key ActionObtain prior authorization and document failure of both a topical prescription-strength antiperspirant and a systemic anticholinergic within the past 6 months; samples do not qualify.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50 unitsrecommended dose per axilla
    400 unitsmaximum cumulative adult dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsminimum symptom duration
    2required prior therapy failures
    J0585HCPCS code

    Coverage and Medical Necessity Criteria

    Initial therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Diagnosis

    • Supportive features: Bilateral, symmetric sweating; Impairment of daily activities; At least one episode per week; Onset before 25 years of age; Positive family history; Cessation of focal sweating during sleep>=2 features

      Check all that apply on form and provide supporting chart notes

    Prior therapy: Member must have had an adequate trial and failure of BOTH a topical prescription‑strength antiperspirant (e.g., DrySol 20% aluminum chloride hexahydrate) AND a systemic anticholinergic agent (e.g., glycopyrrolate, oxybutynin, clonidine) within the past six (6) monthsBoth therapies failed within 6 months

    Failure must be verified by pharmacy paid claims or chart notes; use of samples does not count

    Documentation and administration: Prescriber must complete and sign the prior authorization form and provide required member/prescriber/drug information, diagnosis and ICD code if applicable, dosing schedule, length of therapy, and weight if applicableForm fully completed with supporting documentation

    Incomplete or missing documentation may delay or result in denial of authorization

    Dosing limits: Dosing should follow recommended dosing and cumulative limits: 50 units per axilla; maximum cumulative adult dose 400 units per 3‑month interval; pediatric maximum is the lower of 10 units/kg body weight or 340 units per 3‑month intervalDose limits must not be exceeded

    Document dosing schedule on request form

    Cosmetic indications are excluded. Requests for botulinum toxin (onabotulinumtoxinA) for cosmetic purposes will not meet medical necessity criteria and should not be approved.

    The use of medication samples to start therapy does not satisfy the plan's step-edit or prior authorization requirements. Use of samples to initiate therapy does not meet step edit/preauthorization criteria, and prior treatment must be verified by pharmacy paid claims or submitted chart notes.

    Billing Codes and Dosing Limits

    Requested drug HCPCSHCPCS
    J0585Botox (onabotulinumtoxinA)
    Maximum cumulative adult dose
    Maximum cumulative adult dose400 units per 3-month interval
    Interval definitionPer policy: in a 3-month interval
    ApplicabilityApplies to adult patients treated for one or more indications
    Recommended dosing per axilla
    Recommended dose per axilla50 units per axilla
    Dosing contextListed under Recommended Dosing for hyperhidrosis treatment
    Use with cumulative limits

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior authorization required for Botox (J0585)

    Botox (onabotulinumtoxinA) (HCPCS J0585) requires prior authorization for treatment of Primary Axillary Hyperhidrosis; all clinical criteria on the form must be met and documented for approval.

    Step Therapy

    Step therapy — required prior treatments

    Member must have documented failure of an adequate trial of BOTH a topical prescription-strength antiperspirant (e.g., DrySol 20% aluminum chloride hexahydrate) AND a systemic anticholinergic (e.g., glycopyrrolate, oxybutynin, clonidine) within the past six months; samples do not qualify as prior therapy.

    • Both therapies must be verified by chart notes and/or pharmacy paid claims
    • Use of samples to initiate therapy does not meet step edit/prior-authorization criteria

    Clinical Background

    Primary axillary hyperhidrosis is characterized by visible, excessive sweating for at least six (6) months that commonly affects both axillae and interferes with daily activities. The diagnosis requires the six-month duration plus at least two supportive features such as bilateral symmetric sweating, impairment of daily activities, at least one episode per week, onset before 25 years, positive family history, or cessation of focal sweating during sleep. Chart notes or other documentation must be submitted to support these findings for authorization.

    Diagnostic Criteria and Definitions

    Primary Axillary Hyperhidrosis diagnostic criteria
    Core diagnostic requirementVisible, excessive sweating for at least six (6) months
    Supportive features requiredAt least two of: bilateral symmetric sweating; impairment of daily activities; at least one episode per week; onset before 25 years; positive family history; cessation of focal sweating during sleep
    DocumentationSubmit chart notes to support each line checked; all checked criteria must be met for approval
    Policy Summary
    PayerAvMed
    PolicyBotulinum toxin Type A (onabotulinumtoxinA) for primary axillary hyperhidrosis — Prior authorization / step-edit criteria
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Last ReviewOct 15, 2024
    Next Review Date
    Key ActionObtain prior authorization and document failure of both a topical prescription-strength antiperspirant and a systemic anticholinergic within the past 6 months; samples do not qualify.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes and Dosing LimitsPrior Authorization, Documentation, and Step TherapyClinical BackgroundDiagnostic Criteria and Definitions
    Follow 50 units per axilla while not exceeding total cumulative dose limits
    Pediatric maximum dose
    Pediatric maximum dose ruleUse the lower of 10 units/kg body weight OR 340 units per 3-month interval
    Interval definitionPer policy: in a 3-month interval
    Applies toPediatric patients (weight-based dosing required)
    Documentation Required

    Required form fields and supporting documentation

    Prescriber must sign and clearly print their name on the prior authorization/step-edit request (preprinted stamps are not valid) and provide required member and prescriber information, diagnosis (with supporting chart notes), dosing schedule and length of therapy; include weight if applicable and pharmacy paid claims or chart notes to verify prior therapies.

    • Signed and printed prescriber name (stamps not valid)
    • Member and prescriber contact information (phone/fax) accurate and legible
    • Diagnosis and supporting chart notes documenting diagnostic criteria (symptom duration ≥6 months and ≥2 supportive features)
    • Dosing schedule and length of therapy; weight if applicable
    • Pharmacy paid claims or chart notes to verify prior therapies
    Denial Risk

    Incomplete documentation may delay or deny authorization

    Authorization may be delayed or denied if the request form is incomplete, incorrect, or illegible, or if required supporting documentation (lab results, diagnostics, chart notes, or pharmacy paid claims substantiating prior therapies and diagnostic criteria) is not provided.

    • Incomplete, incorrect, or illegible information on the form can delay authorization
    • Missing chart notes, diagnostics, lab results, or pharmacy paid claims to support criteria may result in denial